BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yao CC, Kuo CM, Hsu CN, Yang SC, Wu CK, Tai WC, Liang CM, Wu KL, Huang CF, Bi KW, Lee CH, Chuah SK. First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus. Infect Drug Resist 2019;12:1425-31. [PMID: 31239721 DOI: 10.2147/IDR.S194584] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Akbari Rad M, Goshayeshi L, Moodi Ghalibaf AA, Mehrad Majd H, Soleimani G, Kolahi Ahari R. Helicobacter pylori Standard Triple Therapy Outcomes in Iranian Population: A Retrospective Population-based Study in Mashhad, Northeast of Iran. Jundishapur J Microbiol 2022;15. [DOI: 10.5812/jjm-127842] [Reference Citation Analysis]
2 Bisht N, P. Garg A. Helicobacter pylori Gastric Infection: Pathogenesis and Clinical Management. Helicobacter pylori Infection - An Up to Date on the Pathogenic Mechanisms, Diagnosis and Clinical Management [Working Title] 2022. [DOI: 10.5772/intechopen.106783] [Reference Citation Analysis]
3 Yadollahi B, Valizadeh Toosi SM, Bari Z, Fakheri H, Maleki I, Taghvaei T, Hosseini V, Kazemi A, Shokri-Afra H. Efficacy of 14-day concomitant quadruple therapy and 14-day high-dose dual therapy on H. pylori eradication. Gastroenterol Hepatol Bed Bench 2022;15:172-8. [PMID: 35845300] [Reference Citation Analysis]
4 Rojas A, Lindner C, Schneider I, Gonzàlez I, Araya H, Morales E, Gómez M, Urdaneta N, Araya P, Morales MA. Diabetes mellitus contribution to the remodeling of the tumor microenvironment in gastric cancer. World J Gastrointest Oncol 2021;13:1997-2012. [PMID: 35070037 DOI: 10.4251/wjgo.v13.i12.1997] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol 2021;21:388. [PMID: 34670526 DOI: 10.1186/s12876-021-01977-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
6 Hackett RJ, Preston SL. H.pylori, part II : management in an era of antibiotic resistance. Trends Urology & Men Health 2021;12:18-24. [DOI: 10.1002/tre.818] [Reference Citation Analysis]
7 Song X, Cai C, Jin Q, Chen X, Yu C. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis. Helicobacter 2021;26:e12781. [PMID: 33465265 DOI: 10.1111/hel.12781] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK. Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice. Infect Drug Resist 2021;14:1239-46. [PMID: 33790594 DOI: 10.2147/IDR.S304711] [Reference Citation Analysis]
9 Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY, Chuah SK. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol 2020;13:1756284820976990. [PMID: 33354229 DOI: 10.1177/1756284820976990] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
10 Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, Zhang X, Cheng H. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study. Helicobacter 2020;25:e12717. [PMID: 32548932 DOI: 10.1111/hel.12717] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 O'Connor A, Furuta T, Gisbert JP, O'Morain C. Review - Treatment of Helicobacter pylori infection 2020. Helicobacter 2020;25 Suppl 1:e12743. [PMID: 32918350 DOI: 10.1111/hel.12743] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
12 Radionova ТО, Skrypnyk IM, Hopko ОF, Kryvoruchko ІG, Skrypnyk RI. PATHOGENETIC SUBSTANTIATION OF EUPATILIN PRESCRIPTION IN PATIENTS WITH CHRONIC HELICOBACTER PYLORI-ASSOCIATED GASTRITIS AND CONCOMITANT TYPE 2 DIABETES MELLITUS. VPBM 2020;2:149. [DOI: 10.29254/2077-4214-2020-2-156-149-154] [Reference Citation Analysis]